Riquent Trial Fails; Is This La Jolla’s Last Gasp?
This article was originally published in The Pink Sheet Daily
Executive Summary
Data monitoring board says continuing ASPEN trial is “futile” after first interim look at BioMarin-licensed Riquent trial for treatment of lupus nephritis.
You may also be interested in...
Two Veteran Biotechs Give Up the Ghost Just as Public Markets Start to Rebound
La Jolla Pharmaceuticals and VaxGen will soon cease to exist, one through liquidation, the other in a fire sale.
Two Veteran Biotechs Give Up the Ghost Just as Public Markets Start to Rebound
La Jolla Pharmaceuticals and VaxGen will soon cease to exist, one through liquidation, the other in a fire sale.
New Business Models Needed For Drug Diagnostic Partnerships
The industry is stymied by outmoded partnership models that don’t adequately value the knowledge of diagnostic makers.